Approval · Notice of Compliance 3241 · 1998
MAVIK: Notice of Compliance 3241
Issued March 25, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3241
- Date
- March 25, 1998
- Company
- Knoll Pharma Inc.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional indication: left ventricular dysfunction after myocardial infarction
- Therapeutic class
- Angiotensin converting enzyme inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAVIK | Not yet assigned | — |
Medicinal ingredients
- TRANDOLAPRIL 0.5 MG per CAP
- TRANDOLAPRIL 1 MG per CAP
- TRANDOLAPRIL 2 MG per CAP